<?xml version="1.0" encoding="UTF-8"?>
<p>A protease inhibitor, lopinavir/ritonavir, which is commonly used to treat HIV/AIDS patients, could be used for the treatment of COVID‐19‐infected patients. Coumarin (
 <bold>62</bold>) (Figure 
 <xref rid="ptr6893-fig-0002" ref-type="fig">2e</xref>) has a broad spectrum of antiviral activity against hepatitis virus, dengue virus, chikungunya virus, and influenza virus by inhibiting viral proteins required for their entry, replication, and infection, and/or by regulation of cellular and antioxidative pathways (Mishra, Pandey &amp; Manvati, 2020). Caffeic acid (
 <bold>63</bold>) and 5‐caffeoylquinic acid (
 <bold>64</bold>) (Figure 
 <xref rid="ptr6893-fig-0002" ref-type="fig">2e</xref>) from 
 <italic>Achyrocline satureioides</italic> inhibit the protein HIV integrase essential for viral DNA integration into host chromatin (Khaerunnisa et al., 
 <xref rid="ptr6893-bib-0031" ref-type="ref">2020</xref>; Robinson, Reinecke, Abdel‐Malek, Jia, &amp; Chow, 
 <xref rid="ptr6893-bib-0062" ref-type="ref">1996</xref>).
</p>
